Answers are grounded in this paper and cite their sources.
ALK-positive Non-Small-Cell Lung Cancer (NSCLC) is a defined subgroup of lung cancer. Crizotinib was the first ALK-inhibitor introduced in clinical practice after two phase III trials demonstrated its superiority over chemotherapy both in second and in first line of treatment. Approximately within ten months patients developed acquired resistance to crizotinib and relapse. Second and third generation ALK-inhibitors are more potent molecules designed to overcome crizotinib resistance. Ceritinib, alectinib and brigatinib are approved by FDA as subsequent therapy in patients who have progressed after crizotinib. Lorlatinib and entrectinib are in different phases of clinical development. Moreover some of these agents are compared to crizotinib in first line setting to evaluate if an upfront more potent inhibitor could control disease longer than a sequential strategy. Despite the efficacy of second-generation ALK inhibitors, patients relapse. Each ALK-inhibitor is characterized by a distinct resistence profile with important clinical consequences in the choice of subsequent therapy.
No takes yet. Share an insight, caveat, or question.
Mazza et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: